548 related articles for article (PubMed ID: 33548185)
1. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
[TBL] [Abstract][Full Text] [Related]
2. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
[TBL] [Abstract][Full Text] [Related]
3. Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening.
Worthington J; van Wifferen F; Sun Z; de Jonge L; Lew JB; Greuter MJE; van den Puttelaar R; Feletto E; Lansdorp-Vogelaar I; Coupé VMH; Ein Yong JH; Canfell K;
EClinicalMedicine; 2023 Aug; 62():102081. PubMed ID: 37538541
[TBL] [Abstract][Full Text] [Related]
4. COVID-related disruptions to colorectal cancer screening, diagnosis, and treatment could increase cancer Burden in Australia and Canada: A modelling study.
Worthington J; Sun Z; Fu R; Lew JB; Chan KKW; Li Q; Eskander A; Hui H; McLoughlin K; Caruana M; Peacock S; Yong JHE; Canfell K; Feletto E; Malagón T
PLoS One; 2024; 19(4):e0296945. PubMed ID: 38557758
[TBL] [Abstract][Full Text] [Related]
5. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
[TBL] [Abstract][Full Text] [Related]
6. Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study.
Luo Q; O'Connell DL; Yu XQ; Kahn C; Caruana M; Pesola F; Sasieni P; Grogan PB; Aranda S; Cabasag CJ; Soerjomataram I; Steinberg J; Canfell K
Lancet Public Health; 2022 Jun; 7(6):e537-e548. PubMed ID: 35660215
[TBL] [Abstract][Full Text] [Related]
7. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada.
Yong JH; Mainprize JG; Yaffe MJ; Ruan Y; Poirier AE; Coldman A; Nadeau C; Iragorri N; Hilsden RJ; Brenner DR
J Med Screen; 2021 Jun; 28(2):100-107. PubMed ID: 33241760
[TBL] [Abstract][Full Text] [Related]
8. A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia.
Nickson C; Smith MA; Feletto E; Velentzis LS; Broun K; Deij S; Grogan P; Hall M; He E; St John DJ; Lew JB; Procopio P; Simms KT; Worthington J; Mann GB; Canfell K
Elife; 2023 Apr; 12():. PubMed ID: 37022767
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
[TBL] [Abstract][Full Text] [Related]
10. Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: A decision analysis to prepare for future screening disruption.
Mandrik O; Chilcott J; Thomas C
Prev Med; 2022 Jul; 160():107076. PubMed ID: 35526674
[TBL] [Abstract][Full Text] [Related]
11. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
[TBL] [Abstract][Full Text] [Related]
12. The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands.
Dinmohamed AG; Cellamare M; Visser O; de Munck L; Elferink MAG; Westenend PJ; Wesseling J; Broeders MJM; Kuipers EJ; Merkx MAW; Nagtegaal ID; Siesling S
J Hematol Oncol; 2020 Nov; 13(1):147. PubMed ID: 33148289
[TBL] [Abstract][Full Text] [Related]
13. Effects of cancer screening restart strategies after COVID-19 disruption.
Kregting LM; Kaljouw S; de Jonge L; Jansen EEL; Peterse EFP; Heijnsdijk EAM; van Ravesteyn NT; Lansdorp-Vogelaar I; de Kok IMCM
Br J Cancer; 2021 Apr; 124(9):1516-1523. PubMed ID: 33723386
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer population screening programs worldwide in 2016: An update.
Navarro M; Nicolas A; Ferrandez A; Lanas A
World J Gastroenterol; 2017 May; 23(20):3632-3642. PubMed ID: 28611516
[TBL] [Abstract][Full Text] [Related]
15. Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe.
Toes-Zoutendijk E; Portillo I; Hoeck S; de Brabander I; Perrin P; Dubois C; van Leerdam M; Lansdorp-Vogelaar I; Bardou M
J Med Screen; 2020 Jun; 27(2):68-76. PubMed ID: 31645173
[TBL] [Abstract][Full Text] [Related]
16. Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis.
van den Puttelaar R; Lansdorp-Vogelaar I; Hahn AI; Rutter CM; Levin TR; Zauber AG; Meester RGS
Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):22-29. PubMed ID: 36215205
[TBL] [Abstract][Full Text] [Related]
17. Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial.
Forsberg A; Westerberg M; Metcalfe C; Steele R; Blom J; Engstrand L; Fritzell K; Hellström M; Levin LÅ; Löwbeer C; Pischel A; Strömberg U; Törnberg S; Wengström Y; Ekbom A; Holmberg L; Hultcrantz R;
Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):513-521. PubMed ID: 35298893
[TBL] [Abstract][Full Text] [Related]
18. Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic.
Issaka RB; Taylor P; Baxi A; Inadomi JM; Ramsey SD; Roth J
JAMA Netw Open; 2021 Apr; 4(4):e216454. PubMed ID: 33843997
[TBL] [Abstract][Full Text] [Related]
19. The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic.
Kortlever TL; de Jonge L; Wisse PHA; Seriese I; Otto-Terlouw P; van Leerdam ME; Spaander MCW; Dekker E; Lansdorp-Vogelaar I
Prev Med; 2021 Oct; 151():106643. PubMed ID: 34217421
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
